Evolution of therapy for limited stage diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), with limited-stage DLBCL defined as stage I or II disease. Risk stratification, initial treatment options, and relapse patterns are distinct from advanced-stage DLBCL, but there is limited data on the impact of biol...

Full description

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2022-02, Vol.12 (2), p.33-33, Article 33
Main Authors: Rojek, Alexandra E., Smith, Sonali M.
Format: Article
Language:English
Subjects:
692/699/67/1059/2325
692/699/67/1059/485
Biological Products
Biology
Biomedical and Life Sciences
Biomedicine
Cancer Research
Chemotherapy
Disease
Evolution
Gene expression
Gene Rearrangement
Hematology
Humans
Lymphoma
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - therapy
Lymphoma, Non-Hodgkin
Medical prognosis
Oncology
Prospective Studies
Radiation
Review
Review Article
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), with limited-stage DLBCL defined as stage I or II disease. Risk stratification, initial treatment options, and relapse patterns are distinct from advanced-stage DLBCL, but there is limited data on the impact of biologic features on outcome. Patients have excellent outcomes, with ~90% survival at 2 years. Over the past several years, sequential prospective trials and large registry studies have evaluated the optimal number of chemotherapy cycles and implemented PET-adapted approaches to reduce the need for radiotherapy. Special consideration must still be given to cases of bulky disease, extranodal disease, fully resected scenarios, and adverse biologic features such as high-grade B-cell lymphoma with double/triple hit rearrangements. This review presents the evolution of a modern management approach, with a discussion of recent treatment-defining studies.
ISSN:2044-5385
2044-5385
DOI:10.1038/s41408-021-00596-z